|
U.S. News Aventis Closer to U.S. Approval for AIDS-Related DrugMarch 26, 2004 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Paris-based Aventis, France's largest drug firm, is one step closer in getting U.S. approval for Sculptra, its injectable wrinkle-filling drug for patients with AIDS-related wasting condition. An advisory panel unanimously voted to recommend Food and Drug Administration approval of Sculptra for people with HIV, while cautioning against more widespread use. Aventis estimates annual sales of the drug to be as much as 1 billion euros (US$1.2 billion). New York Times 03.26.04; Bloomberg News A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|